التفاصيل البيبلوغرافية
| العنوان: |
Commentary: Ticagrelor monotherapy—Not for CABG? |
| المؤلفون: |
Sandner, Sigrid1 (AUTHOR) sigrid.sandner@meduniwien.ac.at, Gaudino, Mario2 (AUTHOR), Kastrati, Adnan3 (AUTHOR) |
| المصدر: |
Journal of Cardiac Surgery. Apr2022, Vol. 37 Issue 4, p1087-1089. 3p. 1 Graph. |
| مستخلص: |
Indeed, the majority of contemporary randomized trials that included imaging follow-up at 1 year have failed to demonstrate a significant benefit of intensified antithrombotic therapy including oral anticoagulation on SVG patency over aspirin5,6,12-14 (Figure 1). Keywords: coronary artery disease; patency; saphenous vein graft; ticagrelor EN coronary artery disease patency saphenous vein graft ticagrelor 1087 1089 3 03/02/22 20220401 NES 220401 Saphenous vein grafts (SVGs) remain the most commonly used conduits in coronary artery bypass grafting (CABG) despite greater rates of both early and late occlusion compared to arterial grafts. In a recent meta-analysis based on aggregate data from 48 studies including 41,530 grafts, the pooled incidence of SVG occlusion within the first year after CABG was estimated at 11%.1 The role of aspirin in the prevention of SVG failure has been firmly established. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
